TY - JOUR
T1 - Diagnostic Cardiovascular Imaging and Therapeutic Strategies in Pregnancy
T2 - JACC Focus Seminar 4/5
AU - American College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group
AU - Bello, Natalie A.
AU - Bairey Merz, C. Noel
AU - Brown, Haywood
AU - Davis, Melinda B.
AU - Dickert, Neal W.
AU - El Hajj, Stephanie C.
AU - Giullian, Cindy
AU - Quesada, Odayme
AU - Park, Ki
AU - Sanghani, Rupa M.
AU - Shaw, Leslee
AU - Volgman, Annabelle Santos
AU - Wenger, Nanette K.
AU - Williams, Dominique
AU - Pepine, Carl J.
AU - Lindley, Kathryn J.
N1 - Funding Information:
Dr. Bello is supported by National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) Grants K23 HL136853-03 and R01 HL153382-01. Dr. Quesada is supported by NIH/NHLBI Gant K23 HL151867-01. Dr. Volgman is supported by NIH/National Institute of Nursing Research (NINR) Grant R01 NR018443 and Novartis TQJ230A12001 epidemiological study on lipoprotein a in patients with CVD. Dr. Bairey Merz serves as Board of Director for iRhythm; and receives personal fees paid through CSMC from Abbott Diagnostics, and Sanofi. Dr. Brown is a co-author on Up to Date–Maternal Mortality. Dr. Volgman has stock ownership in Apple Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2021 American College of Cardiology Foundation
PY - 2021/4/13
Y1 - 2021/4/13
N2 - The prevalence of cardiovascular disease (CVD) in pregnancy, both diagnosed and previously unknown, is rising, and CVD is a leading cause of maternal morbidity and mortality. Historically, women of child-bearing potential have been underrepresented in research, leading to lasting knowledge gaps in the cardiovascular care of pregnant and lactating women. Despite these limitations, clinicians should be familiar with the safety of frequently used diagnostic and therapeutic interventions to adequately care for this at-risk population. This review, the fourth of a 5-part series, provides evidence-based recommendations regarding the use of common cardiovascular diagnostic tests and medications in pregnant and lactating women.
AB - The prevalence of cardiovascular disease (CVD) in pregnancy, both diagnosed and previously unknown, is rising, and CVD is a leading cause of maternal morbidity and mortality. Historically, women of child-bearing potential have been underrepresented in research, leading to lasting knowledge gaps in the cardiovascular care of pregnant and lactating women. Despite these limitations, clinicians should be familiar with the safety of frequently used diagnostic and therapeutic interventions to adequately care for this at-risk population. This review, the fourth of a 5-part series, provides evidence-based recommendations regarding the use of common cardiovascular diagnostic tests and medications in pregnant and lactating women.
KW - cardio-obstetrics
KW - imaging
KW - lactation
KW - medication
KW - pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85103292337&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2021.01.056
DO - 10.1016/j.jacc.2021.01.056
M3 - Review article
C2 - 33832607
AN - SCOPUS:85103292337
SN - 0735-1097
VL - 77
SP - 1813
EP - 1822
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 14
ER -